Effects of a novel, potent benzothiazepine Ca2+ channel antagonist, DTZ323, on guinea-pig ventricular myocytes.
The effects of a 1,5-benzothiazepine derivative, (+)-cis-3-(acetyloxy)-5-[2-[[2-(3,4-dimethoxyphenyl)ethyl]-methyla mino]ethyl]-2,3-dihydro-2-(4-methyoxyphenyl)-1,5-benzothiazepine-4 (5H)-one (DTZ323), on membrane currents were investigated in guinea-pig ventricular myocytes using the whole-cell patch-clamp technique. DTZ323 suppressed the L-type Ca2+ channel currents (I[Ca(L)]) more selectively than the T-type Ca2+ channel and the Na+ channel currents. DTZ323 inhibited I[Ca(L)] in a use- and a voltage-dependent manner with 24 times higher potency than that of diltiazem. Rate of recovery of I[Ca(L)] from the conditioned block by DTZ323 was faster compared with diltiazem and verapamil, and was steeply dependent on the holding potential at resting membrane potential range in ventricular myocytes (-90 to -60 mV). Our results suggest that DTZ323 is a selective Ca2+ channel antagonist, the most potent among the 1,5-benzothiazepine Ca2+ channel antagonists, and that the voltage- and use-dependent effect of DTZ323 on I[Ca(L)] is due to the steep voltage dependence of the rate of dissociation from the cardiac L-type Ca2+ channels.